Press Releases
Samsung Biologics Wins 2018 CMO Leadership Awards in All Six Core Categories Two Years in a Row
[NY, USA] March 21, 2018 ? Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, is pleased to announce that it has won all six core categories two years in a row in the 7th annual CMO Leadership Awards presented by Life Science Leader.
The company has received CMO Leadership Awards including this year’s awards for the fifth consecutive year since 2013, proving Samsung’s highest quality of biologics manufacturing service to global customers
“The awards are in recognition of the highest level of accomplishment that drug development and manufacturing organizations have attained in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “They are especially meaningful because recipients are only evaluated by the customers they have actually worked with, and include the six critical categories of capabilities, compatibility, expertise, quality, reliability and service. An award in any of these categories adds to the distinction and reputation of CMOs throughout the global drug discovery, development, manufacturing and marketing industries.”
For the 2018 CMO Leadership Awards, more than 110 CMOs around the world were evaluated on 23 performance metrics to determine winners in the six categories.
“Industry Standard Research is honored to conduct the market research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high caliber of qualification required to participate in our contract manufacturing benchmarking market research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.” Andrew Schafer, President of Industry Standard Research.
"Samsung Biologics is honored to once again receive the CMO Leadership Award, which recognizes the reputable partner for global customer’s manufacturing needs. Being recognized in all core criteria ? capabilities, compatibility, expertise, quality, reliability and service ? attests to our solid position as a one stop service provider for mammalian biopharmaceutical products through our flexible and state of-the-art facilities,” said TH Kim, CEO of Samsung BioLogic. “We'll continue to provide quality-driven CGMP manufacturing for flexible and cost-effective services that exceed our customers’ expectations.”
Samsung Biologics, being responsible from clinical development to commercial manufacturing, aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality products for the patient.
Samsung Biologics’ Plant 3 facility was mechanically completed last November. It has 180,000 liters capacity and is expected to be CGMP operational by Q4 2018.
-E N D ?
[NY, USA] March 21, 2018 – Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, is pleased to announce that it has won all six core categories two years in a row in the 7th annual CMO Leadership Awards presented by Life Science Leader.
The company has received CMO Leadership Awards including this year’s awards for the fifth consecutive year since 2013, proving Samsung’s highest quality of biologics manufacturing service to global customers
“The awards are in recognition of the highest level of accomplishment that drug development and manufacturing organizations have attained in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “They are especially meaningful because recipients are only evaluated by the customers they have actually worked with, and include the six critical categories of capabilities, compatibility, expertise, quality, reliability and service. An award in any of these categories adds to the distinction and reputation of CMOs throughout the global drug discovery, development, manufacturing and marketing industries.”
For the 2018 CMO Leadership Awards, more than 110 CMOs around the world were evaluated on 23 performance metrics to determine winners in the six categories.
“Industry Standard Research is honored to conduct the market research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high caliber of qualification required to participate in our contract manufacturing benchmarking market research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.” Andrew Schafer, President of Industry Standard Research.
"Samsung Biologics is honored to once again receive the CMO Leadership Award, which recognizes the reputable partner for global customer’s manufacturing needs. Being recognized in all core criteria – capabilities, compatibility, expertise, quality, reliability and service – attests to our solid position as a one stop service provider for mammalian biopharmaceutical products through our flexible and state of-the-art facilities,” said TH Kim, CEO of Samsung BioLogic. “We'll continue to provide quality-driven CGMP manufacturing for flexible and cost-effective services that exceed our customers’ expectations.”
Samsung Biologics, being responsible from clinical development to commercial manufacturing, aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality products for the patient.
Samsung Biologics’ Plant 3 facility was mechanically completed last November. It has 180,000 liters capacity and is expected to be CGMP operational by Q4 2018.
-E N D –